Company intelligence / Profile preview

Ancora Medical Technology

Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

The platform demonstrates clinical efficacy across multiple conditions. For type 2 diabetes (SLIMMER program), results show 50% reduction in diabetes risk, 5% weight loss, 87% satisfaction, and 21% reduction in primary care consultations. The platform is deployed across multiple care settings in Europe.

Therapeutic areas: OtherEndocrinologyCardiovascular
Modalities: Digital therapeuticsRemote patient monitoringAI-driven clinical decision support
Industry: Digital Health Medical Devices

Partnerships

Healthcare systems and providers across Europe

Beyond the preview

Go deeper on Ancora Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ancora Medical Technology.

Explore the full profile